Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAPA-DEINE #4 vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Mild to moderate pain,Pain accompanied by fever
Relief of moderate to moderately severe pain
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
2-4 hours. In hepatic or renal impairment, half-life may increase to 4-6 hours, requiring dose adjustment.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Acetaminophen: Primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3); a minor pathway via CYP2E1 yields toxic NAPQI, which is detoxified by glutathione. Codeine: Metabolized by CYP2D6 to morphine (active), and by CYP3A4 to norcodeine.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Renal: ~90% (70% as glucuronide conjugates, 10% as morphine, 10% as normorphine). Biliary/fecal: ~10%.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
35% bound to albumin.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
3-5 L/kg. Large Vd indicates extensive tissue distribution.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral: 40-50% (first-pass effect). IV: 100%.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
Cr Cl 30-50 m L/min: extend dosing interval to every 6-8 hours; Cr Cl <30 m L/min: not recommended due to risk of acetaminophen accumulation and codeine toxicity.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh Class C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Weight-based: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours as needed; maximum acetaminophen 75 mg/kg/day, codeine limited due to CYP2D6 variability and risk of respiratory depression.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Initiate with lowest effective dose (e.g., 1 tablet every 6 hours), monitor for respiratory depression, constipation, and falls; avoid in frail elderly or those with impaired renal/hepatic function; use with caution due to increased sensitivity and slower metabolism.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Acetaminophen: Risk of severe liver injury (hepatotoxicity) with doses exceeding 4000 mg per day or in patients with hepatic impairment. Codeine: Risk of respiratory depression, especially in children, and risk of opioid addiction, abuse, and misuse.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Hepatotoxicity (acetaminophen), respiratory depression (codeine), opioid-induced hyperalgesia, tolerance, dependence, withdrawal, risk of serotonin syndrome with serotonergic drugs, risk of adrenal insufficiency, severe hypotension, seizure, and increased intracranial pressure.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hypersensitivity to acetaminophen or codeine, severe hepatic impairment, acute or severe bronchial asthma, respiratory depression, paralytic ileus, suspected or known gastrointestinal obstruction, use of MAO inhibitors within 14 days.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid excessive intake of caffeine-containing foods or beverages as papaverine may increase caffeine effects. No specific food interactions known, but take with food if gastrointestinal upset occurs.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
PAPA-DEINE #4 (acetaminophen 300 mg + codeine phosphate 30 mg). Acetaminophen is generally considered low risk in pregnancy; codeine is associated with increased risk of congenital malformations, particularly respiratory and cardiac defects, in first trimester. Chronic use in third trimester may lead to neonatal opioid withdrawal syndrome (NOWS). Use only if clearly needed and at lowest effective dose for shortest duration.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Acetaminophen enters breast milk in low amounts (M/P ratio ~0.91), considered compatible. Codeine is present in breast milk; M/P ratio ~2.3. In mothers who are CYP2D6 ultrarapid metabolizers, codeine can produce toxic morphine levels in infant, leading to risk of neonatal opioid toxicity (CNS depression, apnea). Contraindicated in lactation unless benefits outweigh risks; prefer non-opioid alternatives.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Pregnancy may alter codeine pharmacokinetics: increased clearance due to enhanced hepatic metabolism and increased renal blood flow. However, no specific dose adjustment is recommended; use lowest effective dose for shortest duration. Avoid in third trimester if possible to prevent neonatal withdrawal.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Papa-Deine #4 contains papaverine, a phosphodiesterase inhibitor, and may cause hypotension; monitor blood pressure closely when used with antihypertensives. Avoid in patients with glaucoma due to anticholinergic effects. Papaverine can cause hepatotoxicity; liver function tests should be monitored.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take this medication exactly as prescribed; do not crush or chew tablets.,Dizziness, drowsiness, or flushed skin may occur; avoid driving until you know how the medication affects you.,Alcohol can increase drowsiness; limit alcohol intake.,Report any vision changes, eye pain, or jaundice to your healthcare provider immediately.,Store at room temperature away from moisture and heat.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAPA-DEINE #4 vs ANEXSIA, answered by our medical review team.
PAPA-DEINE #4 is a Opioid Analgesic Combination that works by Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAPA-DEINE #4 and ANEXSIA depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAPA-DEINE #4 is: 1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAPA-DEINE #4 and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAPA-DEINE #4 is classified as Category C. PAPA-DEINE #4 (acetaminophen 300 mg + codeine phosphate 30 mg). Acetaminophen is generally considered low risk in pregnancy; codeine is associated with increased risk of congenital. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.